EVOLVE: A Multicenter Open-Label Single-Arm Clinical and Translational Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer after PARP Inhibition Progression
- 14 August 2020
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 26 (16), 4206-4215
- https://doi.org/10.1158/1078-0432.ccr-19-4121
Abstract
Background: PARP inhibitors (PARPis) are standard-of-care therapy for high-grade serous ovarian cancer (HGSOC). We investigated combining cediranib (antiangiogenic) with olaparib (PARPi) at emergence of PARPi resistance. Methods: The proof-of-concept EVOLVE study (NCT02681237) assessed cediranib-olaparib combination therapy after progression on a PARPi. Women with HGSOC and radiographic evidence of disease progression were enrolled into one of three cohorts: platinum sensitive after PARPi; platinum resistant after PARPi; or progression on standard chemotherapy after progression on PARPi (exploratory cohort). Patients received olaparib tablets 300 mg twice daily with cediranib 20 mg once daily until progression or unacceptable toxicity. The co-primary endpoints were objective response rate (RECIST v1.1) and progression-free survival (PFS) at 16 weeks. Archival tissue (PARPi-naïve) and baseline biopsy (post-PARPi) samples were mandatory. Genomic mechanisms of resistance were assessed by whole-exome and RNA sequencing. Results: Among 34 heavily pretreated patients, objective responses were observed in 0/11 (0%) platinum-sensitive patients, 2/10 (20%) platinum-resistant patients, and 1/13 (8%) in the exploratory cohort. 16-week PFS rates were 55%, 50%, and 39%, respectively. The most common grade 3 toxicities were diarrhea (12%) and anemia (9%). Acquired genomic alterations at PARPi progression were reversion mutations in BRCA1, BRCA2, or RAD51B (19%), CCNE1 amplification (16%), ABCB1 upregulation (15%), and SLFN11 downregulation (7%). Patients with reversion mutations in homologous recombination genes and/or ABCB1 upregulation had poor outcomes. Conclusion: This is currently the largest post-PARPi study identifying genomic mechanisms of resistance to PARPis. In this setting, the activity of cediranib-olaparib varied according to the PARPi resistance mechanism.Other Versions
Funding Information
- Princess Margaret Cancer Foundation
- Ontario Institute for Cancer Research
This publication has 48 references indexed in Scilit:
- Sensitive detection of somatic point mutations in impure and heterogeneous cancer samplesNature Biotechnology, 2013
- STAR: ultrafast universal RNA-seq alignerBioinformatics, 2012
- Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian CancerThe New England Journal of Medicine, 2012
- VarScan 2: Somatic mutation and copy number alteration discovery in cancer by exome sequencingGenome Research, 2012
- Secondary Somatic Mutations RestoringBRCA1/2Predict Chemotherapy Resistance in Hereditary Ovarian CarcinomasJournal of Clinical Oncology, 2011
- Integrated genomic analyses of ovarian carcinomaNature, 2011
- Fast and accurate short read alignment with Burrows–Wheeler transformBioinformatics, 2009
- PAnnBuilder: an R package for assembling proteomic annotation dataBioinformatics, 2009
- Resistance to therapy caused by intragenic deletion in BRCA2Nature, 2008
- Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancersNature, 2008